Market Overview

UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Related BSX
Benzinga's Top Upgrades
Goldman Sachs Upgrades Boston Scientific To Neutral

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.

Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company."

Boston Scientific Corporation closed at $7.59 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy
Sep 2014NeedhamInitiates Coverage onHold

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters